Order Article Reprints

Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Fernández C, Iglesias JL, Corral G, Pérez-Ramos L, Montilla L, et al. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study. Pharmaceuticals. 2024; 17(2):182. https://doi.org/10.3390/ph17020182

Moreno, Irene, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, and et al. 2024. "Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study" Pharmaceuticals 17, no. 2: 182. https://doi.org/10.3390/ph17020182

Moreno, I., Hernández, T., Calvo, E., Fudio, S., Kahatt, C., Fernández, C., Iglesias, J. L., Corral, G., Pérez-Ramos, L., Montilla, L., Zeaiter, A., & Lubomirov, R. (2024). Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study. Pharmaceuticals, 17(2), 182. https://doi.org/10.3390/ph17020182